
Novartis AG NVS
$ 161.79
-3.04%
Annual report 2025
added 02-28-2026
Novartis AG DSO Ratio 2011-2026 | NVS
Annual DSO Ratio Novartis AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 0.045 | 0.0412 | - | 75.3 | 76.4 | 69.8 | 78.3 | 79.5 | 76.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 79.5 | 0.0412 | 56.9 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
115 | $ 20.24 | -2.22 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
20.6 | $ 0.82 | -2.95 % | $ 4.47 M | ||
|
Axsome Therapeutics
AXSM
|
105 | $ 165.96 | -0.25 % | $ 8.26 B | ||
|
AbCellera Biologics
ABCL
|
173 | $ 3.74 | -2.23 % | $ 1.12 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Codexis
CDXS
|
32.9 | $ 0.97 | -4.87 % | $ 71.2 M | ||
|
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
59.5 | $ 24.04 | 0.67 % | $ 2.94 B | ||
|
Champions Oncology
CSBR
|
66.5 | $ 5.96 | -1.81 % | $ 81.4 M | ||
|
Daré Bioscience
DARE
|
877 | $ 1.58 | -1.87 % | $ 13.4 M | ||
|
DBV Technologies S.A.
DBVT
|
71.3 | $ 21.89 | -5.85 % | $ 2.12 B | ||
|
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | ||
|
Capricor Therapeutics
CAPR
|
31.9 | $ 25.75 | -4.13 % | $ 690 M | ||
|
Eton Pharmaceuticals
ETON
|
30.4 | $ 17.52 | -3.47 % | $ 449 M | ||
|
Exelixis
EXEL
|
43.4 | $ 40.72 | -0.76 % | $ 11.1 B | ||
|
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | ||
|
Amicus Therapeutics
FOLD
|
62.3 | $ 14.35 | -0.1 % | $ 4.43 B | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
Galapagos NV
GLPG
|
56.5 | $ 32.94 | -3.37 % | $ 2.69 B | ||
|
Genmab A/S
GMAB
|
97.9 | $ 27.53 | -7.17 % | $ 17.6 B | ||
|
GeoVax Labs
GOVX
|
36.6 | $ 1.53 | -1.92 % | $ 2.78 M | ||
|
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
Halozyme Therapeutics
HALO
|
93.4 | $ 69.01 | -1.2 % | $ 8.27 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
4.13 | $ 3.17 | -5.09 % | $ 1.13 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Agios Pharmaceuticals
AGIO
|
47.4 | $ 28.49 | -2.57 % | $ 1.65 B | ||
|
Harmony Biosciences Holdings
HRMY
|
37.8 | $ 28.56 | -1.18 % | $ 1.64 B | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M |